References
- DiPippo AJ, Rausch CR, Kontoyiannis DP. Tolerability of isavuconazole
after posaconazole toxicity in leukaemia patients. Mycoses .
2019;62(1):81-6.
- Spellberg B, Rieg G, Bayer A, Edwards JE, Jr. Lack of
cross-hepatotoxicity between fluconazole and voriconazole. Clin
Infect Dis . 2003;36(8):1091-3.
- Foo H, Gottlieb T. Lack of Cross-Hepatotoxicity between Voriconazole
and Posaconazole. Clin Infect Dis . 2007;45(6):803-5.
- Martínez-Casanova J, Carballo N, Luque S, Sorli L, Grau S.
Posaconazole achieves prompt recovery of voriconazole-induced liver
injury in a case of invasive aspergillosis. Infection Drug
Resistance . 2018;11:317-21.
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5
[Internet]. US Department of Health and Human Services, National
Institutes of Health, National Cancer Institute.
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the
probability of adverse drug reactions. Clin Pharmacol Ther .
1981;30(2):239-45.
- LiverTox: Clinical and Research Information on Drug-Induced Liver
Injury [Internet]: Bethesda (MD): National Institute of Diabetes
and Digestive and Kidney Diseases; [Available from:
livertox.nih.gov/.
- Egunsola O, Adefurin A, Fakis A, et al. Safety of fluconazole in
paediatrics: a systematic review. Eur J Clin Pharmacol .
2013;69(6):1211-21.
- Somchit N, Wong CW, Zuraini A, et al. Involvement of phenobarbital and
SKF 525A in the hepatotoxicity of antifungal drugs itraconazole and
fluconazole in rats. Drug Chem Toxicol . 2006;29(3):237-53.
- Haegler P, Joerin L, Krähenbühl S, Bouitbir J. Hepatocellular Toxicity
of Imidazole and Triazole Antimycotic Agents. Toxicol Sci .
2017;157(1):183-95.
- Neely M, Rushing T, Kovacs A, Jelliffe R, Hoffman J. Voriconazole
pharmacokinetics and pharmacodynamics in children. Clin Infect
Dis . 2010;50(1):27-36.
Table I: Overview of patients with azole-induced hepatotoxicity whose
liver functions tests improved after switching to another triazole
antifungal